Efforts to develop effective therapies for MYC-amplified Group 3 medulloblastoma (G3-MB) are hindered by an incomplete ...
--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...
A tumor-specific enhancer on extrachromosomal DNA drives MYC expression, revealing a new therapeutic target in high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results